Literature DB >> 24378262

Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C.

Nicola Coppola1, Ivan Gentile2, Giuseppe Pasquale1, Antonio Riccardo Buonomo2, Nicolina Capoluongo1, Maria D'Armiento3, Guglielmo Borgia2, Evangelista Sagnelli1.   

Abstract

INTRODUCTION. In patients with chronic hepatitis C it is still debated whether previous exposure to the hepatitis B virus, diagnosed from the presence of the anti-HBc antibody, is linked to a greater risk of severe hepatitis. The aim of the study was to evaluate whether the presence of anti-HBc antibodies is associated with cirrhosis in patients with HBsAg-negative chronic hepatitis C. MATERIAL AND METHODS. Two hundred twenty-two consecutive HBsAg-negative patients with HCV-related chronic hepatitis were enrolled at their first liver biopsy. Ishak's scoring system was used to grade necroinflammation and fibrosis and the patients with stage 5 or 6 were considered as having histological cirrhosis. RESULTS. Patients with histological cirrhosis had a higher mean age, AST, ALT, a lower platelet count and prothrombin activity compared to those with milder fibrosis. The presence of anti-HBc was identified in 21 (63.6%) of the 33 patients with fibrosis score 5 or 6 and in 56 (29.6%; p < 0.001) of the 189 with score ≤ 4. Patients with cirrhosis had a significantly higher grading than those without cirrhosis (median = 8, IQR 6-11 vs. Median = 6, IQR = 4-8, respectively, p < 0.001). A multivariate logistic regression analysis showed that age, sex and anti-HBc positivity were independent predictors of histological cirrhosis. CONCLUSION. Our data support the idea that in patients with chronic hepatitis C the presence in serum of anti-HBc is associated with histological cirrhosis and is therefore a marker of clinical value.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24378262

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  12 in total

1.  Interferon-free regimens improve kidney function in patients with chronic hepatitis C infection.

Authors:  Nicola Coppola; Federica Portunato; Antonio Riccardo Buonomo; Laura Staiano; Riccardo Scotto; Biagio Pinchera; Stefania De Pascalis; Daniela Caterina Amoruso; Salvatore Martini; Mariantonietta Pisaturo; Carmine Coppola; Ivan Gentile
Journal:  J Nephrol       Date:  2019-04-11       Impact factor: 3.902

Review 2.  Role of occult hepatitis B virus infection in chronic hepatitis C.

Authors:  Nicola Coppola; Lorenzo Onorato; Mariantonietta Pisaturo; Margherita Macera; Caterina Sagnelli; Salvatore Martini; Evangelista Sagnelli
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 3.  Clinical impact of occult hepatitis B virus infection in immunosuppressed patients.

Authors:  Evangelista Sagnelli; Mariantonietta Pisaturo; Salvatore Martini; Pietro Filippini; Caterina Sagnelli; Nicola Coppola
Journal:  World J Hepatol       Date:  2014-06-27

Review 4.  Hepatic flares in chronic hepatitis C: spontaneous exacerbation vs hepatotropic viruses superinfection.

Authors:  Evangelista Sagnelli; Caterina Sagnelli; Mariantonietta Pisaturo; Nicola Coppola
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

Review 5.  Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy.

Authors:  Evangelista Sagnelli; Caterina Sagnelli; Mariantonietta Pisaturo; Margherita Macera; Nicola Coppola
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

Review 6.  Occult HBV infection in the oncohematological setting.

Authors:  C Sagnelli; M Macera; M Pisaturo; R Zampino; M Coppola; E Sagnelli
Journal:  Infection       Date:  2016-04-13       Impact factor: 3.553

7.  Occult HBV infection status and its impact on surgical outcomes in patients with curative resection for HCV-associated hepatocellular carcinoma.

Authors:  Koutaro Yamaji; Keita Kai; Sho Komukai; Hiroki Koga; Takao Ide; Atsushi Kawaguchi; Hirokazu Noshiro; Shinichi Aishima
Journal:  Hepatobiliary Surg Nutr       Date:  2018-12       Impact factor: 7.293

Review 8.  Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection.

Authors:  Ivan Gentile; Antonio Riccardo Buonomo; Emanuela Zappulo; Giuseppina Minei; Filomena Morisco; Francesco Borrelli; Nicola Coppola; Guglielmo Borgia
Journal:  Ther Clin Risk Manag       Date:  2014-06-26       Impact factor: 2.423

9.  Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease: A meta-analysis.

Authors:  Nicola Coppola; Lorenzo Onorato; Caterina Sagnelli; Evangelista Sagnelli; Italo F Angelillo
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

Review 10.  Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C?

Authors:  Silvia Martina Ferrari; Poupak Fallahi; Ilaria Ruffilli; Giusy Elia; Francesca Ragusa; Sabrina Rosaria Paparo; Armando Patrizio; Valeria Mazzi; Michele Colaci; Dilia Giuggioli; Clodoveo Ferri; Alessandro Antonelli
Journal:  J Immunol Res       Date:  2019-08-08       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.